Venus Remedies granted Market Authorizations in Saudi Arabia and Philippines

Venus Remedies Ltd has received Marketing Authorizations for Paclitaxel 100m9/16.7rn1 and Zolendronic Acid 4mg in the Philippines, located in the dynamic region of Asia (South East).

ln addition, the company has also secured il/larketing Authorization for Bleomycin 15IU from SaudiArabia. These regulatory approvals signify a significant milestone for Venus Remedies Limited, reflecting the company's commitment to advancing healthcare solutions and expanding its global presence. The company is dedicated to delivering high-quality pharmaceuticals that contribute to improving patient outcomes and addressing critical medical needs.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 386.25 as compared to the previous close of Rs. 387.60. The total number of shares traded during the day was 32827 in over 1659 trades.

The stock hit an intraday high of Rs. 402.40 and intraday low of 384.00. The net turnover during the day was Rs. 12901697.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 MarketingAuthorizations Paclitaxel